 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «1234567» |
- lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Enrollment change: Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2) (clinicaltrials.gov) - Jul 23, 2016
P3, N=8, Terminated, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
N=210 --> 8
- ||||| Pegasys (pegylated interferon ? -2a) / Roche
Trial initiation date, Combination therapy: A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase (clinicaltrials.gov) - May 5, 2016
P3, N=114, Recruiting, Sponsor: Hoffmann-La Roche
N=210 --> 8 Initiation date: Feb 2007 --> Jun 2014
- entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation (clinicaltrials.gov) - Apr 26, 2016
P4, N=17, Terminated, Sponsor: Taichung Veterans General Hospital
Initiation date: Feb 2007 --> Jun 2014 N=98 --> 17 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Apr 2016; Slow progress in recruiting study patients
- | Tyzeka (telbivudine) / Novartis
Trial completion, Post-transplantation: Replacement of Lamivudine by Telbivudine to Improve Renal Function (clinicaltrials.gov) - Apr 8, 2016
P2/3, N=120, Completed, Sponsor: Chang Gung Memorial Hospital
N=98 --> 17 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Apr 2016; Slow progress in recruiting study patients Enrolling by invitation --> Completed
- lamivudine HBV / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial primary completion date: Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients (clinicaltrials.gov) - Apr 1, 2016
P4, N=160, Recruiting, Sponsor: Taipei Veterans General Hospital, Taiwan
Enrolling by invitation --> Completed Trial primary completion date: Dec 2016 --> Dec 2019
- lamivudine HBV / Generic mfg., adefovir dipivoxil / Generic mfg.
Enrollment closed: TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA (clinicaltrials.gov) - Mar 16, 2016
P4, N=171, Active, not recruiting, Sponsor: Keimyung University Dongsan Medical Center
Trial primary completion date: Dec 2016 --> Dec 2019 Enrolling by invitation --> Active, not recruiting
- ||||| Pegasys (pegylated interferon ? -2a) / Roche
Trial initiation date, Trial primary completion date, Combination therapy: A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase (clinicaltrials.gov) - Mar 4, 2016
P3, N=114, Recruiting, Sponsor: Hoffmann-La Roche
Enrolling by invitation --> Active, not recruiting Initiation date: Feb 2007 --> Dec 2014 | Trial primary completion date: Jan 2024 --> Apr 2024
- ||||| Pegasys (pegylated interferon ? -2a) / Roche
Trial initiation date, Combination therapy: A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase (clinicaltrials.gov) - Feb 2, 2016
P3, N=114, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Feb 2007 --> Dec 2014 | Trial primary completion date: Jan 2024 --> Apr 2024 Initiation date: Dec 2014 --> Feb 2007
- entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial completion: Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=50, Completed, Sponsor: The University of Hong Kong
Initiation date: Dec 2014 --> Feb 2007 Active, not recruiting --> Completed
- || Pegasys (pegylated interferon ? -2a) / Roche
Trial primary completion date: A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (clinicaltrials.gov) - Dec 4, 2015
P4, N=255, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Sep 2008 --> Apr 2009
- entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial primary completion date: Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine (clinicaltrials.gov) - Nov 19, 2015
P3, N=180, Recruiting, Sponsor: Seoul National University Hospital
Trial primary completion date: Sep 2008 --> Apr 2009 Trial primary completion date: Dec 2015 --> Dec 2016
- ||||| Pegasys (pegylated interferon ? -2a) / Roche
New P4 trial: A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (clinicaltrials.gov) - Nov 6, 2015
P4, N=255, Completed, Sponsor: Hoffmann-La Roche
- |||| Pegasys (pegylated interferon ? -2a) / Roche
Trial primary completion date, Combination therapy: A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase (clinicaltrials.gov) - Aug 21, 2015
P3, N=114, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Mar 2023 --> Jan 2024
- lamivudine HBV / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, HEOR, Cost effectiveness: Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=621, Active, not recruiting, Sponsor: Beijing Friendship Hospital
Trial primary completion date: Mar 2023 --> Jan 2024 Recruiting --> Active, not recruiting | N=800 --> 621 | Trial primary completion date: Dec 2014 --> Dec 2015
- || Tyzeka (telbivudine) / Novartis
New P2/3 trial, Post-transplantation: Replacement of Lamivudine by Telbivudine to Improve Renal Function (clinicaltrials.gov) - May 19, 2015
P2/3, N=120, Enrolling by invitation, Sponsor: Chang Gung Memorial Hospital
- Tyzeka (telbivudine) / Novartis
Trial completion: Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B (clinicaltrials.gov) - May 10, 2015
P3, N=0, Completed, Sponsor: Novartis
Recruiting --> Active, not recruiting | N=800 --> 621 | Trial primary completion date: Dec 2014 --> Dec 2015 No longer recruiting --> Completed
- Tyzeka (telbivudine) / Novartis
Trial completion: An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B (clinicaltrials.gov) - May 10, 2015
P2b, N=0, Completed, Sponsor: Novartis
No longer recruiting --> Completed No longer recruiting --> Completed
- Tyzeka (telbivudine) / Novartis
Trial completion: A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B (clinicaltrials.gov) - Mar 18, 2015
P3, N=0, Completed, Sponsor: Novartis
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| lamivudine HBV / Generic mfg.
Trial completion, Combination therapy, Monotherapy: Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine (clinicaltrials.gov) - Mar 7, 2015
P3, N=280, Completed, Sponsor: Gilead Sciences
No longer recruiting --> Completed Active, not recruiting --> Completed
- |||| entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial completion, Enrollment change: Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA (clinicaltrials.gov) - Mar 7, 2015
P4, N=72, Completed, Sponsor: Pusan National University Hospital
Active, not recruiting --> Completed Recruiting --> Completed | N=200 --> 72
- | lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
New P4 trial: Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents (clinicaltrials.gov) - Jan 13, 2015
P4, N=500, Recruiting, Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
- ||||| Pegasys (pegylated interferon ? -2a) / Roche
Trial initiation date, Combination therapy: A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase (clinicaltrials.gov) - Dec 30, 2014
P3, N=114, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | N=200 --> 72 Initiation date: Dec 2013 --> Dec 2014
- ||||| Pegasys (pegylated interferon ? -2a) / Roche
Trial initiation date, Combination therapy: A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase (clinicaltrials.gov) - Dec 25, 2014
P3, N=114, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Dec 2013 --> Dec 2014 Initiation date: May 2014 --> Dec 2013
- |||| entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial primary completion date: Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine (clinicaltrials.gov) - Nov 23, 2014
P3, N=180, Recruiting, Sponsor: Seoul National University Hospital
Initiation date: May 2014 --> Dec 2013 Trial primary completion date: Jun 2014 --> Dec 2015
- |||||||||| Pegasys (pegylated interferon ? -2a) / Roche
New P3 trial, Combination therapy: A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase (clinicaltrials.gov) - Oct 15, 2014
P3, N=114, Recruiting, Sponsor: Hoffmann-La Roche
- ||||| lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
New P4 trial, Combination therapy, Monotherapy: Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects (clinicaltrials.gov) - Jul 30, 2014
P4, N=192, Completed, Sponsor: Southeast University, China
- lamivudine HBV / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial completion, Trial primary completion date: Lamivudine and Adefovir to Treat Chronic Hepatitis B (clinicaltrials.gov) - Jul 27, 2014
P2, N=41, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Trial primary completion date: Jun 2014 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Jul 2010 --> Apr 2010
- entecavir / Generic mfg., lamivudine HBV / Generic mfg.
Trial primary completion date: Lactic Acidosis During Entecavir(ETV)Treatment (clinicaltrials.gov) - Jun 27, 2014
P4, N=5, Terminated, Sponsor: Asan Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Jul 2010 --> Apr 2010 Trial primary completion date: May 2013 --> Sep 2013
- entecavir / Generic mfg., lamivudine HBV / Generic mfg.
Trial termination: Lactic Acidosis During Entecavir(ETV)Treatment (clinicaltrials.gov) - Jun 27, 2014
P4, N=5, Terminated, Sponsor: Asan Medical Center
Trial primary completion date: May 2013 --> Sep 2013 Not yet recruiting --> Terminated; Tenofovir has become available in Korea.
- entecavir / Generic mfg., lamivudine HBV / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Lactic Acidosis During Entecavir(ETV)Treatment (clinicaltrials.gov) - Jun 27, 2014
P4, N=5, Terminated, Sponsor: Asan Medical Center
Not yet recruiting --> Terminated; Tenofovir has become available in Korea. N=90 --> 5 | Not yet recruiting --> Terminated | Trial primary completion date: May 2013 --> Sep 2013; Tenofovir has become available in Korea.
- lamivudine HBV / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial completion date: Lamivudine and Adefovir to Treat Chronic Hepatitis B (clinicaltrials.gov) - Apr 24, 2014
P2, N=41, Active, not recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
N=90 --> 5 | Not yet recruiting --> Terminated | Trial primary completion date: May 2013 --> Sep 2013; Tenofovir has become available in Korea. Trial completion date: Sep 2013 --> Sep 2017
- || Pegasys (pegylated interferon ? -2a) / Roche
Biomarker, Enrollment change: A Retrospective Biomarker Study of Stored Samples Obtained From Patients With Chronic Hepatitis B (clinicaltrials.gov) - Apr 24, 2014
P=N/A, N=269, Completed, Sponsor: Hoffmann-La Roche
Trial completion date: Sep 2013 --> Sep 2017 N=1300 --> 269
- ||| Pegasys (pegylated interferon ? -2a) / Roche
Biomarker, Trial completion: A Retrospective Biomarker Study of Stored Samples Obtained From Patients With Chronic Hepatitis B (clinicaltrials.gov) - Apr 24, 2014
P=N/A, N=269, Completed, Sponsor: Hoffmann-La Roche
N=1300 --> 269 Recruiting --> Completed
- ||||||| Tyzeka (telbivudine) / Novartis
Trial completion: Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis (clinicaltrials.gov) - Feb 22, 2014
P3, N=232, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial completion: Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients (clinicaltrials.gov) - Feb 22, 2014
P2/3, N=0, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed No longer recruiting --> Completed
- entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial completion: A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine (clinicaltrials.gov) - Feb 22, 2014
P3, N=0, Completed, Sponsor: Bristol-Myers Squibb
No longer recruiting --> Completed No longer recruiting --> Completed
- entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial completion: A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen (clinicaltrials.gov) - Feb 22, 2014
P3, N=0, Completed, Sponsor: Bristol-Myers Squibb
No longer recruiting --> Completed No longer recruiting --> Completed
- entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial completion: A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen (clinicaltrials.gov) - Feb 22, 2014
P3, N=0, Completed, Sponsor: Bristol-Myers Squibb
No longer recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV (clinicaltrials.gov) - Feb 22, 2014
P2, N=90, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed No longer recruiting --> Completed
- | lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial completion: Lamivudine for Chronic Hepatitis B (clinicaltrials.gov) - Feb 19, 2014
P2, N=60, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
No longer recruiting --> Completed No longer recruiting --> Completed
- | Trial completion, Combination therapy: Adefovir and Lamivudine for Entecavir Resistance (ALTER Study) (clinicaltrials.gov) - Feb 13, 2014
P4, N=20, Completed, Sponsor: Korea University
No longer recruiting --> Completed Active, not recruiting --> Completed
- Tyzeka (telbivudine) / Novartis
Enrollment closed: Antiviral Efficacy of Switching to ETV Plus TDF (clinicaltrials.gov) - Jan 29, 2014
P4, N=104, Active, not recruiting, Sponsor: Yonsei University
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- |||| entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial completion: A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection (clinicaltrials.gov) - Jan 6, 2014
P4, N=122, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Enrollment change: Resistance to Lamivudine in HBV Egyptian Patients (clinicaltrials.gov) - Sep 7, 2013
P=N/A, N=230, Completed, Sponsor: Ain Shams University
Active, not recruiting --> Completed N=100 --> 230
- lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial completion: Resistance to Lamivudine in HBV Egyptian Patients (clinicaltrials.gov) - Sep 7, 2013
P=N/A, N=230, Completed, Sponsor: Ain Shams University
N=100 --> 230 Recruiting --> Completed
- lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial completion: A Study to Investigate Whether the Immediate Use or Deferred Use of an Anti-viral Drug Lamivudine Will Help to Better Safe-guard the Delivery of Chemotherapy in Patients With Cancer Who Are Also Hepatitis B Carriers (clinicaltrials.gov) - Sep 2, 2013
P=N/A, N=110, Completed, Sponsor: Hospital Authority, Hong Kong
Recruiting --> Completed Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
New P2 trial: Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL (clinicaltrials.gov) - Jul 31, 2013
P2, N=82, Recruiting, Sponsor: Fudan University
- |||| Tyzeka (telbivudine) / Novartis
Trial completion: Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B (clinicaltrials.gov) - Jul 28, 2013
P4, N=700, Completed, Sponsor: Beijing YouAn Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Tyzeka (telbivudine) / Novartis
Trial termination: SASL28: Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine (clinicaltrials.gov) - Jun 19, 2013
P4, N=27, Terminated, Sponsor: University Hospital, Basel, Switzerland
Active, not recruiting --> Completed Recruiting --> Terminated; unsufficient patient recruitment
- Tyzeka (telbivudine) / Novartis
Enrollment change: SASL28: Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine (clinicaltrials.gov) - Jun 19, 2013
P4, N=27, Terminated, Sponsor: University Hospital, Basel, Switzerland
Recruiting --> Terminated; unsufficient patient recruitment N=160 --> 27